Experience in Borderline Ovarian Tumors

NCT ID: NCT05791838

Last Updated: 2023-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-31

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Borderline Ovarian Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years,
* Patients affected by borderline ovarian tumors (BOT) of any histological type and any FIGO stage,
* Women undergoing surgical treatment with both laparoscopic and laparotomic approaches.

Exclusion Criteria

\- Women affected by ovarian cancers
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Palermo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andrea Etrusco

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Basilio Pecorino, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Catania

Paolo Scollo, M.D. Ph.D.

Role: STUDY_DIRECTOR

University of Catania

Antonio Simone Laganà, M.D. Ph.D.

Role: STUDY_CHAIR

University of Palermo

Andrea Etrusco, M.D.

Role: STUDY_CHAIR

University of Palermo

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andrea Etrusco, M.D.

Role: CONTACT

+393881715032

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BOT-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.